Innovating Works

Epi-IBD

Financiado
Using an organoid model to understand epithelial immunity in IBD
As the first line of defense against intestinal pathogens, gut epithelial cells are an essential part of the immune system. They may play an important role in immune-mediated diseases such as Inflammatory Bowel Disease (IBD). IBD... As the first line of defense against intestinal pathogens, gut epithelial cells are an essential part of the immune system. They may play an important role in immune-mediated diseases such as Inflammatory Bowel Disease (IBD). IBD is a group of disorders characterized by chronic inflammation of the gastrointestinal tract. IBD prevalence is high in Western countries (0.3% in 2018) and it is rising in newly industrialized countries. A prevailing model is that the interplay of two factors may cause IBD. First, a genetic predisposition weakens the gut immune system and causes high susceptibility to bacterial infection. Second, pathogenic bacteria infect the gut and trigger chronic inflammation. It is still unclear how the gut immune system may fail to repress bacterial infection in IBD. Historically, most studies have been focusing on immune cells of the hematopoietic lineage, such as macrophages and lymphocytes. However, the role of gut epithelial cells in controlling gut microbes is now gaining increasing attention. In this project, I propose to use organoids composed of differentiated intestinal cells to study how the intestinal epithelium responds to bacterial infection in the context of IBD. I will establish an in vitro model of IBD based on human small intestine organoids. I will infect the organoids with the bacterium Adherent-Invasive Escherichia coli (AIEC) and study how the differentiated intestinal cells respond to AIEC invasion. I will both test the relevance of a well-known IBD genetic predisposition (the mutation 1007fs in Nucleotide-binding oligomerization domain 2 (Nod2)) and explore novel mechanisms underlying the immune response of gut epithelial cells using RNAseq and CRISPR base editing. My project will dissect the molecular mechanisms of IBD. In addition, it will improve our understanding of the immune response of epithelial cells, which are an under-studied component of the immune system. ver más
31/08/2026
188K€
Duración del proyecto: 41 meses Fecha Inicio: 2023-03-30
Fecha Fin: 2026-08-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 188K€
Líder del proyecto
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCH... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5